Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

被引：0
|
作者：
Bernard J. Smilde
Clemens Stockklausner
Richard Keen
Andrew Whittaker
Alex N. Bullock
Annette von Delft
Natasja M. van Schoor
Paul B. Yu
E. Marelise W. Eekhoff
机构：
[1] Amsterdam UMC location Vrije Universiteit Amsterdam,Department of Internal Medicine Section Endocrinology
[2] Amsterdam Movement Sciences,Tissue Function and Regeneration
[3] Klinikum Garmisch-Partenkirchen,Department of Paediatrics
[4] Royal National Orthopaedic Hospital,Department of Rheumatology
[5] BioPharmaceuticals R&D,Emerging Innovations Unit, Discovery Sciences
[6] AstraZeneca,Centre for Medicines Discovery, Nuffield Department of Medicine
[7] University of Oxford,Oxford Biomedical Research Centre, National Institute for Health Research
[8] University of Oxford,Epidemiology and Data Science
[9] Amsterdam UMC location Vrije Universiteit Amsterdam,Aging and Later Life
[10] Amsterdam Public Health,Cardiovascular Research Center
[11] Massachusetts General Hospital,undefined
来源：
BMC Musculoskeletal Disorders | / 23卷
关键词：
Fibrodysplasia Ossificans Progressiva; Saracatinib; AZD0530; Clinical trial; Drug repurposing; Drug repositioning;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Efficacy and safety of Jia Wei Bushen Yiqi formulas as an adjunct therapy to systemic glucocorticoids on acute exacerbation of COPD: study protocol for a randomized, double-blinded, multi-center, placebo-controlled clinical trial
    Qing Kong
    Shuming Mo
    Wenqian Wang
    Zihui Tang
    Ying Wei
    Yijie Du
    Baojun Liu
    Lingwen Kong
    Yubao Lv
    Jingcheng Dong
    Trials, 21
  • [22] Efficacy and safety of Jia Wei Bushen Yiqi formulas as an adjunct therapy to systemic glucocorticoids on acute exacerbation of COPD: study protocol for a randomized, double-blinded, multi-center, placebo-controlled clinical trial
    Kong, Qing
    Mo, Shuming
    Wang, Wenqian
    Tang, Zihui
    Wei, Ying
    Du, Yijie
    Liu, Baojun
    Kong, Lingwen
    Lv, Yubao
    Dong, Jingcheng
    TRIALS, 2020, 21 (01)
  • [23] EFFICACY AND SAFETY OF LINAGLIPTIN IN BLACK/AFRICAN AMERICAN PATIENTS WITH TYPE 2 DIABETES: A 6-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Thrasher, James
    Daniels, Kristen
    Patel, Sanjay
    Whetteckey, Jacqueline
    Woerle, Hans-Juergen
    ENDOCRINE PRACTICE, 2014, 20 (05) : 412 - 420
  • [24] Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial
    McLaughlin, Pamela M. J.
    Klar, Maximilian
    Zwimpfer, Tibor A.
    Dutilh, Gilles
    Vetter, Marcus
    Marth, Christian
    du Bois, Andreas
    Schade-Brittinger, Carmen
    Reuss, Alexander
    Bommer, Claudine
    Kurzeder, Christian
    Heinzelmann-Schwarz, Viola
    BMC CANCER, 2022, 22 (01)
  • [25] Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial
    Pamela M. J. McLaughlin
    Maximilian Klar
    Tibor A. Zwimpfer
    Gilles Dutilh
    Marcus Vetter
    Christian Marth
    Andreas du Bois
    Carmen Schade-Brittinger
    Alexander Reuss
    Claudine Bommer
    Christian Kurzeder
    Viola Heinzelmann-Schwarz
    BMC Cancer, 22
  • [26] Correction to: the efficacy and safety of total glucosides of peony in the treatment of primary Sjögren’s syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial
    Xia Liu
    Xiaomei Li
    Xiangpei Li
    Zhijun Li
    Dongbao Zhao
    Shengyun Liu
    Miaojia Zhang
    Fengxiao Zhang
    Ping Zhu
    Jinwei Chen
    Wei Wei
    Bing Lin
    Yingbo Zhou
    Jing Chen
    Yafei Pang
    Lei Zhang
    Xiaoxuan Sun
    Zhibo Yu
    Yun Jia
    Jia Wang
    Wenwen Sun
    Frank Chiu
    Liping Pang
    Guochun Wang
    Clinical Rheumatology, 2019, 38 : 617 - 618
  • [27] A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan
    Higuchi, Teruhiko
    Kamijima, Kunitoshi
    Nakagome, Kazuyuki
    Itamura, Rio
    Asami, Yuko
    Kuribayashi, Kazuhiko
    Imaeda, Takayuki
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2016, 31 (01) : 8 - 19
  • [28] Study protocol: a multi-center, double-blind, randomized, 6-month, placebo-controlled trial to investigate the effect of supplementing hormone therapy FET cycles with Gushen'antai pills on the outcomes of in vitro fertilization
    Ma, Ying-jie
    Cao, Xian-ling
    Ma, Ting
    Song, Jing-yan
    Yu, Ling-yu
    Yu, Yang-yang
    Zhao, Jian-Yun
    Sun, Zhen-Gao
    TRIALS, 2021, 22 (01)
  • [29] Study protocol: a multi-center, double-blind, randomized, 6-month, placebo-controlled trial to investigate the effect of supplementing hormone therapy FET cycles with Gushen’antai pills on the outcomes of in vitro fertilization
    Ying-jie Ma
    Xian-ling Cao
    Ting Ma
    Jing-yan Song
    Ling-yu Yu
    Yang-yang Yu
    Jian-Yun Zhao
    Zhen-Gao Sun
    Trials, 22
  • [30] Maintenance Therapy with an Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO/LOGOS): study protocol of a randomized double-blinded placebo-controlled multi-center Phase III Trial
    McLaughlin, P. M. J.
    Klar, M.
    Heitz, F.
    Zwimpfer, T. A.
    Dutilh, G.
    Vetter, M.
    Marth, C.
    du Bois, A.
    Schade-Brittinger, C.
    Reuss, A.
    Bommer, C.
    Kurzeder, C.
    Heinzelmann, V
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (10) : E124 - E124
12345